Literature DB >> 30738856

Lung transplantation for idiopathic pulmonary fibrosis.

Peter M George1, Caroline M Patterson2, Anna K Reed3, Muhunthan Thillai4.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis. Lung transplantation is the only intervention shown to increase life expectancy for patients with IPF, but it is associated with disease-specific challenges. In this Review, we discuss the importance of a proactive approach to the management of IPF comorbidities, including gastro-oesophageal reflux, pulmonary hypertension, coronary artery disease, and malignancy. With a donor pool too small to meet demand and unacceptably high mortality on transplant waiting lists, we discuss different systems used internationally to facilitate organ allocation. We explore the rapidly evolving landscape of transplantation for patients with IPF with regards to antifibrotic therapy, technological advances in extracorporeal life support, advances in understanding of the genetics of the disease, and the importance of a holistic multidisciplinary approach to care. Finally, we consider potential advances over the next decade that are envisaged to improve transplantation outcomes in patients with advanced IPF.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30738856     DOI: 10.1016/S2213-2600(18)30502-2

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


  38 in total

Review 1.  Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.

Authors:  Keshava Rajagopal; Andrew J Bryant; Sandeep Sahay; Nancy Wareing; Yang Zhou; Lavannya M Pandit; Harry Karmouty-Quintana
Journal:  Br J Pharmacol       Date:  2020-04-07       Impact factor: 8.739

Review 2.  Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).

Authors:  Shigeki Saito; Ala Alkhatib; Jay K Kolls; Yasuhiro Kondoh; Joseph A Lasky
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

3.  Construction and Validation of a Novel Prognostic Signature of Idiopathic Pulmonary Fibrosis by Identifying Subtypes Based on Genes Related to 7-Methylguanosine Modification.

Authors:  Tao Huang; Wei-Ying He
Journal:  Front Genet       Date:  2022-06-09       Impact factor: 4.772

4.  IPF pathogenesis is dependent upon TGFβ induction of IGF-1.

Authors:  Danielle M Hernandez; Jeong-Han Kang; Malay Choudhury; Mahefatiana Andrianifahanana; Xueqian Yin; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2020-02-17       Impact factor: 5.191

Review 5.  Ca2+ signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases.

Authors:  Katy M Roach; Peter Bradding
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

6.  Single-Cell Reconstruction of Human Basal Cell Diversity in Normal and Idiopathic Pulmonary Fibrosis Lungs.

Authors:  Gianni Carraro; Apoorva Mulay; Changfu Yao; Takako Mizuno; Bindu Konda; Martin Petrov; Daniel Lafkas; Joe R Arron; Cory M Hogaboam; Peter Chen; Dianhua Jiang; Paul W Noble; Scott H Randell; Jonathan L McQualter; Barry R Stripp
Journal:  Am J Respir Crit Care Med       Date:  2020-12-01       Impact factor: 21.405

7.  m6A modification regulates lung fibroblast-to-myofibroblast transition through modulating KCNH6 mRNA translation.

Authors:  Jia-Xiang Zhang; Pei-Jie Huang; Da-Peng Wang; Wen-Yu Yang; Jian Lu; Yong Zhu; Xiao-Xiao Meng; Xin Wu; Qiu-Hai Lin; Hui Lv; Hui Xie; Rui-Lan Wang
Journal:  Mol Ther       Date:  2021-06-08       Impact factor: 11.454

8.  Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition.

Authors:  Qi Wang; Juan Liu; Yinan Hu; Ting Pan; Yongjian Xu; Jun Yu; Weining Xiong; Qing Zhou; Yi Wang
Journal:  Theranostics       Date:  2021-05-13       Impact factor: 11.600

9.  Proteomics and metabonomics analyses of Covid-19 complications in patients with pulmonary fibrosis.

Authors:  Jianrong Yang; Chunxia Chen; Wan Chen; Luying Huang; Zhao Fu; Kun Ye; Liwen Lv; Zhihuang Nong; Xing Zhou; Wensheng Lu; Mei Zhong
Journal:  Sci Rep       Date:  2021-07-16       Impact factor: 4.379

10.  Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis.

Authors:  H Jessen; N Hoyer; T S Prior; P Frederiksen; M A Karsdal; D J Leeming; E Bendstrup; J M B Sand; S B Shaker
Journal:  Respir Res       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.